BCCIP regulates homologous recombination by distinct domains and suppresses spontaneous DNA damage by Lu, Huimei et al.
7160–7170 Nucleic Acids Research, 2007, Vol. 35, No. 21 Published online 18 October 2007
doi:10.1093/nar/gkm732
BCCIP regulates homologous recombination by
distinct domains and suppresses spontaneous
DNA damage
Huimei Lu
1, Jingyin Yue
1, Xiangbing Meng
2, Jac A. Nickoloff
2 and Zhiyuan Shen
1,*
1Department of Radiation Oncology, The Cancer Institute of New Jersey, UMDNJ-Robert Wood Johnson
Medical School, 195 Little Albany Street, New Brunswick, NJ 08903 and
2Department of Molecular
Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA
Received April 11, 2007; Revised August 8, 2007; Accepted September 4, 2007
ABSTRACT
Homologous recombination (HR) is critical for
maintaining genome stability through precise
repair of DNA double-strand breaks (DSBs) and
restarting stalled or collapsed DNA replication forks.
HR is regulated by many proteins through distinct
mechanisms. Some proteins have direct enzymatic
roles in HR reactions, while others act as accessory
factors that regulate HR enzymatic activity or
coordinate HR with other cellular processes such
as the cell cycle. The breast cancer susceptibility
gene BRCA2 encodes a critical accessory protein
that interacts with the RAD51 recombinase
and this interaction fluctuates during the cell
cycle. We previously showed that a BRCA2- and
p21-interacting protein, BCCIP, regulates BRCA2
and RAD51 nuclear focus formation, DSB-induced
HR and cell cycle progression. However, it has not
been clear whether BCCIP acts exclusively through
BRCA2 to regulate HR and whether BCCIP
also regulates the alternative DSB repair pathway,
non-homologous end joining. In this study, we found
that BCCIP fragments that interact with BRCA2 or
with p21 each inhibit DSB repair by HR. We further
show that transient down-regulation of BCCIP in
human cells does not affect non-specific integration
of transfected DNA, but significantly inhibits homo-
logy-directed gene targeting. Furthermore, human
HT1080 cells with constitutive down-regulation of
BCCIP display increased levels of spontaneous
single-stranded DNA (ssDNA) and DSBs. These
data indicate that multiple BCCIP domains are
important for HR regulation, that BCCIP is unlikely
to regulate non-homologous end joining, and
that BCCIP plays a critical role in resolving sponta-
neous DNA damage.
INTRODUCTION
Mammalian cell genomes suﬀer signiﬁcant DNA damage
from endogenous and exogenous agents. Some forms
of DNA damage can block and ultimately cause collapse
of replication forks. Genome instability may result if
DNA damage is incorrectly repaired or blocked replica-
tion forks are not resolved properly. DNA homologous
recombination (HR) plays a major role in the accurate
repair of DNA double-strand breaks (DSBs) and
the resolution of stalled or collapsed replication forks
(1). HR deﬁciency and HR dysregulation has been linked
to genome instability and predisposition to cancer (2,3).
Thus, it is critical to understand how HR is regulated.
HR is regulated at several levels. Some proteins, such as
RAD51 and RAD54 play direct enzymatic roles in HR
reactions. RAD51 binds to single-stranded DNA
(ssDNA), forming nucleoprotein ﬁlaments that are
essential for the homology search and strand invasion.
Defects in these genes typically reduce HR frequencies
and may also alter HR outcomes (4). Other proteins, such
as BRCA2, appear to act as accessory factors, facilitating
the assembly or disassembly of RAD51 ﬁlaments (5–7).
Additional proteins may serve to coordinate HR
activity with other cellular processes such as cell cycle
control. For example, a C-terminal RAD51 binding
domain of BRCA2 coordinates the BRCA2-RAD51
interaction with cell cycle status (8). Thus, BRCA2
has at least two functions in HR, facilitating RAD51
ﬁlament assembly and coordinating HR activity with
the cell cycle. Proteins such as BLM and Top3a regulate
HR at late stages, assisting in resolving recombination
intermediates (9,10).
*To whom correspondence should be addressed. Tel: 732-235-6101; Fax: 732-235-7493; Email: shenzh@umdnj.edu
 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.A highly conserved C-terminal domain of human
BRCA2 includes three tandem RPA-like domains that
bind ssDNA (11). This domain also interacts with several
proteins, including BCCIP, originally identiﬁed as a
BRCA2 and p21 interacting protein (12–14). Human
BCCIP protein has two major isoforms, BCCIPa (322
amino acids) and BCCIPb (314 amino acids), which share
an N-terminal acidic domain (amino acids 1–59) and a
central conserved domain (amino acids 60–258), but have
distinct C-terminal domains (12,15). The BRCA2 interac-
tion domain of BCCIP was mapped to amino acids 59–167
(16), and the p21 interaction domain of BCCIP was
mapped to aa168–258 (14). Consistent with a role for
BCCIP in the DNA damage response, partial down-
regulation of BCCIP impairs BRCA2 and RAD51 nuclear
focus formation (16), and inhibits DSB-induced HR
by 20-to100-fold (16). These results support the idea
that BCCIP regulates HR through its interactions
with BRCA2. Note however, that truncations in BRCA2
itself resulted in only modest HR reductions: 2- to 6-fold
reduction in mouse ES cells expressing BRCA2 lack-
ing exon 27 (17,18) and 2- to 12-fold reduction in
human Capan-1 cells that express truncated BRCA2
(19). This suggests that the marked reduction in HR
with partial BCCIP knockdown is not due solely to the
disruption of the BCCIP-BRCA2 interaction.
In this study, we found that two distinct BCCIP
domains exert dominant negative eﬀects on HR, including
fragments comprising the BRCA2-interaction region
and the p21 interaction region, suggesting that BCCIP
regulates HR by at least two mechanisms. In addition,
we found that transient BCCIP down-regulation signiﬁ-
cantly inhibits gene targeting eﬃciency but not random
integration of a targeting vector, indicating that BCCIP
functions in HR but not non-homologous end joining
(NHEJ). A  50% down-regulation of BCCIP is able to
cause the accumulation of ssDNA and DSB in the
nucleus, probably as a result of failed or ineﬃcient
repair of spontaneous DNA damage. These results
provide further support for the critical roles of BCCIP
in HR regulation and the maintenance of genome
stability.
MATERIALS AND METHODS
Cell culture
HT1080 and HT256 cells were cultured in a-MEM
medium with 10% fetal bovine serum (Hyclone, Logan,
UT, USA), 1% each of penicillin and streptomycin
and 1% glutamine (Invitrogen, Grand island, NY,
USA), at 378C with 5% CO2.
BCCIP over-expression
Two approaches were used to over-express BCCIP and
its fragments. For I-SceI induced HR assays, cDNAs
coding for the full-length BCCIP or fragments were fused
with the myc-epitope in the pCMV-Myc vector. These
vectors were transfected into HT256 cells for transient
expression of BCCIP and fragments. The pCMV-Myc
empty vector was used as negative control. For gene
targeting assay, a large population (>10 million) of cells
was needed. In this case, adenoviruses were produced
as described by He et al. (20). Adenoviruses that over-
express myc-BCCIPa, myc-BCCIPb, myc-BCCIP-D
(aa59–167) and myc-BCCIP-G (aa168–258) were con-
structed by inserting corresponding cDNA fragments into
pCMV-myc (Clontech, Palo Alto, CA, USA) to make
pCMV-myc/BCCIPa, pCMV-myc/BCCIPb, pCMV-myc/
BCCIP-D (aa59–167) and pCMV-myc/BCCIP-G
(aa168–258). The myc-tagged BCCIP coding regions in
these vectors were then ampliﬁed and transferred into the
NotI and XbaI sites of the pAdTracker-CMV shuttle
vector. The recombinant adenoviral vectors were gener-
ated by HR between pAdTrack-CMV shuttle vectors
containing BCCIP inserts and an adenoviral vector, and
correct constructs were conﬁrmed by the presence of 3.0 or
4.5kb PacI digestion fragments. Adenoviruses were
collected from packaging cells 10 days after transfection
by ﬁve freeze/thaw cycles followed by centrifugation.
Ad293 packaging cells were infected with virus super-
natants to further amplify adenovirus vectors. To achieve
100% infection of cell populations, adenoviruses were
titered by monitoring GFP expression after infection of
HT1080 cells. Conﬁrmation of BCCIP fragment expres-
sion was performed by western blot 3 days after infection.
Adenovirus expressing GFP protein was used as the
negative control.
BCCIPand BRCA2 knockdown
For gene targeting assays, adenoviruses expressing
BCCIP-shRNA and BRCA2-shRNA as reported pre-
viously (16) were used. For constitutive knockdown of
BCCIP (Figures 4 and 5), the strategy reported previously
was used (21,22). Brieﬂy, cells were transfected with
pPUR/U6-BCCIPab311 that express a BCCIP-shRNA
targeted at a common region of BCCIPa and BCCIPb.
Within 2–3 weeks after selection with puromycin, the cells
with constitutive BCCIP-shRNA expression were used to
detect spontaneous ssDNA and phosphorylated H2AX
(gH2AX). During this time period, the expression of the
BCCIP was typically down-regulated by  50% as
revealed by western blots.
Immunofluorescent detection ofBCCIP
HT1080 cells were grown on coverslips, ﬁxed with 4%
paraformaldehyde for 10min, washed three times with
PBS and then treated with 0.2% Triton  -100. After
blocking with 3% BSA in TBS-T (25mM Tris–HCl/pH
7.5, 150mM NaCl and 0.1% Tween 20), slides were
incubated with a 1:300 dilution of BCCIP antibody
overnight at 48C for the detection of endogenous BCCIP
(12), or with anti-myc antibodies for the detection of myc-
tagged BCCIP. Slides were washed with TBS-T four times,
incubated with FITC-conjugated anti-IgG secondary
antibody (Jackson Immunoresearch Laboratories, Inc.
West Grove, PA, USA) for 1h at room temperature. After
washing, slides were mounted with mounting media with
DAPI (40, 6-diamidino-2-phenylindole) and imaged with a
Zeiss ﬂuorescent microscope with a digital camera.
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The neo direct repeat HR substrate in HT256 cells has
one neo inactivated by an insertion of an I–SceI site and
the second lacks a promoter (16). HT256 cells were
co-transfected by Geneporter (Gene Therapy Systems,
San Diego, CA, USA) with 2mg pCMV-(HA-3xNLS)-
ISceI, which expresses HA- and NLS-tagged I–SceI
and 2mg of each BCCIP fragment expression vector.
The empty vector pCMV-Myc was used as negative
control. Forty eight hours later, 2 10
5 cells were seeded
to 10cm dishes and G418 resistant clones were identiﬁed
following 2 weeks growth in medium containing 325mg/ml
G418. The number of viable cells seeded to G418 medium
was determined by seeding 200 cells to 10cm dishes
with growth medium lacking G418 and scoring colonies
after 7–10 days.
Gene targeting assayin HT1080cells
The hypoxanthine guanine phosphoribosyl transferase
(HPRT) gene targeting approach developed by Yanez
and Porter was used to measure HR-mediated
gene targeting and random integration in HT1080 cells
(23–25). HT1080 cells contain a single copy of HPRT on
the X-chromosome. The gene targeting vector developed
by Yanez and Porter (23–25), pHPRT-hyg (Figure 2A),
was electroporated into HT1080 cells using a Bio-Rad
GenePulser Xcell electroporator (Bio-Rad Laboratories,
Inc. Hercules, CA, USA) using a 4mm cuvette at 400 volts
and 250mF pulse. Random vector integration confers
hygromycin resistance, but not 6-thioguanine (6TG)
resistance, whereas targeted integration into HPRT
confers resistance to both hygromycin and 6TG
(Figure 2A). Thus, selection with hygromycin with or
without 6TG provides a measures of both random and
targeted integration (23–25).
Because a large number of cells were needed and
transfection was not an option for the gene targeting
assay, adenovirus infection was used to ensure that
the BCCIP down-regulation or over-expression was
achieved in a large population of cells. Based on western
blot analysis, modulation of BCCIP expression was
most eﬀective at day 3 after adenovirus infection
(data not shown). Three days after infection with
adenovirus expression of BCCIP-shRNA, myc-BCCIPa,
myc-BCCIPb, BRCA2-shRNA, myc-BCCIP-D or myc-
BCCIP-G, 10
7 cells were electroporated with 10 mgo f
SalI-digested pHPRT-hyg targeting vector (25) and cells
were transferred to three sets of dishes. In the ﬁrst set,
three dishes were seeded with 500 cells in non-selective
medium to determine the number of viable cells after
electroporation. In the second set, three dishes were
seeded with 5 10
5 cells and 48h later 200mg/ml of
hygromycin was added to determine the frequency of total
integration. In the third set, dishes were seeded with 10
6
cells and 48h later 200 mg/ml hygromycin was added, the
cells were incubated for 3 more days and 15mg/ml 6TG
was added, to determine the HPRT targeting frequency.
The colonies were stained with crystal violet and were
scored after 9–12 days of intial plating.
Statistical analysis ofgene targeting efficiency
Gene targeting is a low probability event and the
formation of satellite 6TG/Hyg-resistant colonies can
lead to signiﬁcant over-estimation of the gene targeting
eﬃciency. Therefore, a Poisson statistics based null
method of Han et al. (26) was used to calculate the
targeting frequency. In this procedure, the numbers of
dishes with zero and at least one 6TG/Hyg-resistant
colonies were counted. The average number of gene
targeted cells per dish was calculated as  ln(y/(x+y)),
where x is the number of dishes with at least one 6TG/
Hyg-resistant colony, y is the number of dishes without
any 6TG/Hyg-resistant colonies and (x+y) is the total
number of dishes, and the standard error was calculated
as (x/y/(x+y))
1/2, according to Balcer-Kubeczek et al.
(27). This approach requires many dishes but eliminates
the possibility of over-estimating the gene targeting
eﬃciency from satellite 6TG/Hyg resistant colonies.
Immunofluorescent detection of ssDNA
The ssDNA was visualized as described (28). Brieﬂy, cells
with 2–3 weeks of constitutive expression of BCCIP-
shRNA were used. During this 2–3 week period, the
expression of BCCIP was typically down-regulated by
 50% as revealed by anti-BCCIP western blots. The cells
were grown on coverslips with 30mmol/l BrdU for 24h in
the dark. This incorporates BrdU into DNA of all dividing
cells. BrdU in ssDNA can be detected by anti-BrdU
antibodies without denaturing the DNA. To visualize total
DNA with incorporated BrdU, cells were ﬁxed in methanol
( 208C) for 10min, treated with 4N HCl for 10–20
minutes at 208C to denature DNA and allow detection of
incorporated BrdU by immunoﬂuorescent staining. After
blocking for 30min at room temperature with 3% bovine
serum albumin in PBS, anti-BrdU antibody (Becton
Dickinson, Franklin Lakes, NJ, USA) was used as
described by the manufacturer. To visualize ssDNA, the
HCl denaturation step was omitted (28).
To quantify the ssDNA in the cells, the numbers of
cells with ﬁve or more nuclear ssDNA foci were counted
from 400 cells in each of the three experiments.
In addition, ssDNA was stained with green ﬂuorescence
as described earlier and the total DNA was stained in blue
with DAPI. Fluorescent images were taken using Carl
Zeiss ﬂuorescent microscope (Axiovert-200M) equipped
with Carl Zeiss digital camera (AxioCam MRC).
The nuclear area was selected with the ImageJ v1.37
software (http://rsb.info.nih.gov/ij/) and ﬂuorescent
signals from ssDNA and total DNA were integrated.
The ratio of ssDNA signal intensity to total DNA
represents the relative level of ssDNA in the nucleus.
For each experiment, at least 50 cells were analyzed. Data
are reported as mean SD from three independent
experiments. Statistical signiﬁcance of ﬂuorescent signal
intensity and ratio of signal intensity in HT1080 BCCIP
wild-type and knockdown cells were analyzed by
two-tailed t-test.
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Two approaches were used to detect gH2AX in BCCIP
knockdown cells: immunoﬂuorescent staining to visualize
the nuclear gH2AX foci and western blot to measure
total gH2AX proteins in the cells. To stain for the gH2AX
foci, HT1080 cells with 2–3 weeks of constitutive
expression of BCCIP-shRNA were grown on coverslips.
During this time period, the expression of BCCIP was
typically down-regulated by  50% as monitored by anti-
BCCIP western blots. Cells were ﬁxed with methanol for
10min and permeabilized with acetone after methanol
ﬁxation. Fixed cells were washed twice in PBS and
suspended in 3% (w/v) solution of bovine serum albumin
(BSA) in PBS for 30min to block non-speciﬁc antibody
binding. Cells were then incubated in 100ml of 3% BSA
containing a 1:100 dilution of anti-gH2AX (Ser-139)
mAb (Upstate, Lake Placid, NY, USA). Cells were
incubated overnight at 48C, washed twice with PBS and
re-suspended in BSA in 100ml of 1:1000 diluted ﬂuor-
escent isothiocyanate (FITC)-conjugated F(ab0)2 frag-
ment of goat anti-mouse immunoglobulin (Jackson
ImmunoResearch Laboratories, Inc.) for 30min at room
temperature in the dark. The cells were counterstained
with DAPI and imaged as reported (29,30). The numbers
of nuclear gH2AX foci were counted. For each experi-
ment, the gH2AX foci from 400 cells were counted. Data
were reported as mean SD from ﬁve independent
experiments. Statistical signiﬁcance between BCCIP
knockdown cells and wild type cells was evaluated by
two-tailed t-test. To conﬁrm the change of gH2AX in
BCCIP knockdown cells, the whole cell lysates from
wild type and BCCIP knockdown cells were analyzed by
western blot using anti-gH2AX speciﬁc antibody.
RESULTS
Inhibition ofDSB induced homologous
recombination by BCCIP fragments
BCCIP was initially identiﬁed by its interactions with
BRCA2 and p21 (12–14,31). It has been established that a
BCCIP region of amino acids 57–167 is responsible for
interaction with BRCA2 and amino acid 168–258 are
responsible for the p21 interaction (12–14,31). BRCA2
regulates HR at least in part through its interactions with
the RAD51 recombinase. BRCA2 interacts with RAD51
in two distinct regions, the BRC repeats and the
C-terminal exon 27 domain. Expression of individual
BRCA2 BRC repeat domains, which interact with
RAD51, has dominant negative eﬀects on DSB-induced
HR (32,33). Because partial BCCIP knockdown strongly
reduces DSB-induced HR (16), we hypothesized that
expression of BCCIP fragments that interact with BRCA2
would similarly reduce HR. In addition, because trunca-
tions of BRCA2 that eliminate the BCCIP binding
domain have weaker HR defects than does BCCIP
knockdown, we further hypothesized that expression of
BCCIP fragments that do not interact with BRCA2 would
also have dominant negative eﬀects on HR. To test these
ideas, a panel of expression vectors expressing BRCA2- or
p21-interaction domains of BCCIP were constructed,
including BCCIP-B (aa1–167), BCCIP-C (aa1–258),
BCCIP-D (aa59–167) and BCCIP-G (aa168–258)
(Figure 1A). The expression of each fragment was
conﬁrmed by immunoﬂuorescence microscopy and by
western blot (Figure 1B and C). The full length BCCIPa
and BCCIPb are mainly expressed in the nucleus as
reported previously (12,16). As shown in Figure 1B,
BCCIP-B and BCCIP-D are expressed both in the
nucleus and the cytoplasm. We fused a synthetic
NLS with fragments BCCIP-B (aa1–167) and BCCIP-D
(aa57–167). As shown in Figure 1B, the addition of an
NLS to BCCIP-B and BCCIP-D greatly increased their
localization to the nucleus.
To determine whether HR repair of DSBs is aﬀected
by expression of full-length BCCIPa or BCCIPb,o r
fragments of BCCIP, we measured HR in cells after
transient expression of I–SceI nuclease in HT256 cells.
HT256 cells are derivatives of human HT1080 cells with a
single-copy, integrated neo direct repeat HR substrate
(16). To minimize potential adverse eﬀects of long-term
constitutive over-expression of BCCIP fragments on
cell growth, BCCIP fragments were transiently expressed
by plasmid transfection and 2 days later cells were
transfected with an I–SceI expression vector to determine
HR frequencies (see Materials and methods section).
As predicted, the BRCA2-interacting fragments
BCCIP-D and BCCIP-B inhibit HR each about
2-fold and both reductions were statistically signiﬁcant
(Figure 1D). Interestingly, the p21 interacting fragment
(BCCIP-G) that does not interact with BRCA2 inhibited
HR to a similar extent. This suggests that, in addition to
interacting with BRCA2, BCCIP regulates HR through its
interactions with other proteins. Note that expression of
a BRCA2 BRC repeat has a similar, 2-fold dominant
negative eﬀect on HR (32).
Inhibition of BCCIP reduces genetargeting
efficiency but notrandom integration
Our prior study (16) and the results above clearly indicate
that BCCIP functions in HR. DSBs can be repaired by
HR or NHEJ, and some proteins function in both
pathways (e.g. BRCA1). To further deﬁne the role of
BCCIP in DSB repair, we analyzed DNA integration
in cells expressing low or high levels of BCCIP.
We transfected HT1080 cells with an HPRT gene
targeting vector (23–25) as this provides simultaneous
measures of random DNA integration, which is mediated
by certain components of the NHEJ machinery (34) and
targeted integration which is mediated by HR (Figure 2A).
Compared to random integration, targeted integration
into HPRT is a low probability event that is best described
by the Poisson statistical distribution. The null method
derived from Poisson distribution (26,27) was used
to calculate the targeting frequency and its standard
error. Because this method requires a large number of
cells for each experiment and long-term constitutive
down-regulation or over-expression of BCCIP may
adversely aﬀect cell growth, we used adenovirues to
transiently reduce or over-express BCCIP in these
Nucleic Acids Research, 2007, Vol. 35, No. 21 7163experiments (see Materials and methods section for
details). Down-regulation of BCCIP by adenovirus
expressing shRNA was found to be maximal 3 days
after the virus infection (data not shown). BCCIP levels
were analyzed by western blot and we observed a
approximately 5-fold decrease in BCCIP in the knock-
down cells and a 2- to 3-fold increase in BCCIP over-
expression cells (Figure 2C). Because HR and NHEJ are
regulated during the cell cycle (35,36), we determined cell-
cycle distributions on day 3 after adenovirus infection.
There were no signiﬁcant changes in distributions at the
time when the targeting vector was electroporated, which
is at day 3 after the transient BCCIP down-regulation or
over-expression by adenovirus infection (Figure 2B).
Cells were therefore transfected with the pHPRT-hyg
targeting vector by electroporation on day 3 after
adenovirus infection. The number of viable cells, hygro-
mycin-resistant transfectants and dishes with 0, 1, 2, 3 or
>3 transfectants resistant to both 6TG and hygromycin
were scored (Table 1). The frequency of random integra-
tion was calculated as the ratio of hygromycin-resistant
transfectants to viable cells and the frequency of gene
targeting was calculated by using the Poisson statistic-
based null method (see Materials and Methods section). As
shown in Figure 2D, BCCIP expression level had no eﬀect
on random integration, indicating that BCCIP is not
involved in NHEJ. However, down-regulation of BCCIP
reduced gene targeting by 2.4-fold, measured either as the
Figure 1. BRCA2- and p21-interacting BCCIP fragments inhibit HR-mediated DSB repair. BCCIP and fragments were expressed from pCMV-Myc
vector after transient transfection. The pCMV-myc empty vector was used as the negative control. (A) Maps of BCCIP fragments tested for eﬀects
on HR. (B) Intracellular distribution of myc-tagged BCCIP fragments detected by anti-Myc immunoﬂuorescence microscopy. (C) Expression of myc-
tagged BCCIP fragments detected by anti-myc western blot. (D) Relative frequencies of HR repair of DSBs in cells transiently expressing myc-tagged
BCCIP fragments.
7164 Nucleic Acids Research, 2007, Vol. 35, No. 21frequency of 6TG- and hygromycin-resistant transfectants
per viable cell (Figure 2E) or as the ratio of 6TG-resistant
to hygromycin-resistant transfectants (Figure 2F), further
supporting the idea that BCCIP functions in HR.
We observed a slight increase in gene targeting with over-
expression of BCCIPa or BCCIPb, but these diﬀerences
were not statistically signiﬁcant (Figure 2E and F).
Expressions of BCCIP-D and BCCIP-Gfragments inhibit
gene targeting
Figure 1 showed that expression of the BRCA2 or p21
interacting regions of BCCIP has dominant negative eﬀect
on I-SceI induced HR in the HT256 cell. To determine
whether the same fragments also aﬀect gene targeting, we
used the adenovirus expressing system to transiently
express the BCCIP-D and BCCIP-G in approximately
10 million cells, and performed the gene targeting assay as
described in Figure 2. The expression of myc-BCCIP-D
and myc-BCCIP-G was conﬁrmed by western blots
(Figure 3A, left panel). In addition, the adenovirus
mediated BRCA2 knockdown as described previously
(16) was used to assess the role of BRCA2 in gene
targeting. As shown by Figure 3A (right panel), this
approach reduced the BRCA2 expression by  50% at day 3
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eﬃciencytransient BCCIPknockdownor over-expressioninHT1080cells. Control,cellsinfectedwithadenovirus expressingGFPalone; shRNA-BCCIP,
cells infected with viruses expressing shRNA against both isoforms of BCCIP; HA-BCCIPa, cells infected with viruses expressing myc-tagged BCCIPa;
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Table 1. Null method for calculating gene targeting eﬃciency in BCCIP modulated cells
Cell type No. of
experiments
No. of
viable cells
per dish
Hyg
R clones
per dish
(Avg SE)
No. of dishes with a speciﬁc number
of 6TG- and Hyg-resistant clones
Targeting
events per dish
(Avg SE)
0 clones 1 clone 2 clones 3 clones total
Control 10 1.90 10
5 133 8 94 30 5 1 130 0.324 0.054
BCCIP-shRNA 10 1.99 10
5 116 12 113 17 0 0 130 0.140 0.034
HA-BCCIPa 4 1.55 10
5 118 7 37 11 2 2 52 0.340 0.088
HA-BCCIPb 4 1.67 10
5 107 5 36 16 0 0 52 0.368 0.092
Nucleic Acids Research, 2007, Vol. 35, No. 21 7165after adenovirus infection. As shown in Figure 3B,
expression of BCCIP-D, BCCIP-G or BRCA2-shRNA
did not signiﬁcantly aﬀect the random integration of the
HPRT targeting vector. However, the homology directed
integration of the targeting vector is signiﬁcantly reduced
by expression of BCCIP-D, BCCIP-G and BRCA2-
shRNA (Figure 3C and D). These data suggest that
both the BRCA2 interacting and p21 interacting regions
of BCCIP have dominant negative eﬀects on homology
based gene integration.
Down-regulation of BCCIP leads toan accumulation of
ssDNAand DSBs
HR plays a critical role in resolving endogenous DNA
damage and restarting stalled replication forks. A key step
in HR is the loading of RAD51 onto ssDNA, which is
thought to be facilitated by BRCA2. If RAD51 is not
loaded onto ssDNA, HR will fail and ssDNA may
accumulate. In addition, the failure to resolve blocked
replication forks is likely to lead to increased levels of
ssDNA, and ultimately lead to fork collapse producing
DSBs. Because down-regulation of BCCIP impairs
RAD51 focus formation (16) and HR, we hypothesized
that BCCIP deﬁciency would lead to the accumulation of
ssDNA and spontaneous DSBs. We used the procedure
developed by Hammond et al. (28) to detect ssDNA.
After 2–3 weeks of constitutive BCCIP knockdown, we
grew cells on coverslips in the presence of bromo-
deoxyuridine (BrdU) for 24h in the dark. During this
time, each cell divides and BrdU is expected to be
uniformly incorporated into DNA. Cells were then stained
with an anti-BrdU antibody, which recognizes incorpo-
rated BrdU in ssDNA. As expected, when total DNA was
denatured prior to incubation with anti-BrdU antibody,
the entire nucleus is stained (Figure 4A). When cells were
0
0.2
0.4
0.6
0.8
1
1.2
0
0.2
0.4
0.6
0.8
1
1.2
0
0.2
0.4
0.6
0.8
1
1.2
R
e
l
a
t
i
v
e
 
r
a
n
d
o
m
 
i
n
t
e
g
r
a
t
i
o
n
R
e
l
a
t
i
v
e
 
g
e
n
e
 
t
a
r
g
e
t
i
n
g
(
n
o
r
m
a
l
i
z
e
d
 
t
o
 
t
o
t
a
l
 
v
i
a
b
l
e
 
c
e
l
l
)
R
e
l
a
t
i
v
e
 
g
e
n
e
 
t
a
r
g
e
t
i
n
g
(
n
o
r
m
a
l
i
z
e
d
 
t
o
 
t
o
t
a
l
 
i
n
t
e
g
r
a
t
i
o
n
)
HygR/Viable
6TGR&HygR/Viable 6TGR&HygR/HygR
C
o
n
t
r
o
l
M
y
c
-
B
C
C
I
P
-
D
M
y
c
-
B
C
C
I
P
-
G
anti-myc blot
anti β-actin
C
o
n
t
r
o
l
B
R
C
A
2
-
s
h
R
N
A
anti-BRCA2
anti-β-actin
A
D
B
C
Control   BCCIP-G BRCA2
shRNA
BCCIP-D
Control   BCCIP-G BRCA2
shRNA
BCCIP-D
Control   BCCIP-G BRCA2
shRNA
BCCIP-D
Figure 3. Expression of BCCIP-D and BCCIP-G fragments inhibit gene targeting. Adenovirus vectors were used to express: myc-BCCIP-D
(aa 59–167), myc-BCCIP-G (aa168–258) and BRCA2-shRNA. Control cells were infected with adenovirus expressing GFP alone. Each group have
total of 84 dishes for 6TGandHyg selection and were assayed in six independent experiments. (A) Western blots (3 days after the virus infection)
conﬁrming the expression of myc-BCCIP-D and myc-BCCIP-G (left panel), and the partial down-regulation of BRCA2 by BRCA2-shRNA (right
panel). (B) Myc-BCCIP-D, myc-BCCIP-G and BRCA2-shRNA do not aﬀect random integration, determined as the total number of hygromycin-
resistant (Hyg
R) colonies per viable cell. Values are averages SE. For all groups compared with the control, the P-values were greater than 0.30 as
tested by two tailed t-test. (C) Myc-BCCIP-D, Myc-BCCIP-G and BRCA2-shRNA reduce gene targeting, determined as the number of Hyg
R and
6TG
R colonies per viable cell. Values are averages SE. For all groups compared with the control, the P-values were less than 0.01 as tested by two
tailed t-test. (D) Myc-BCCIP-D, Myc-BCCIP-G and BRCA2-shRNA reduce gene targeting, determined as the number of 6TG
R colonies per Hyg
R
colony. Values are averages SE. For all groups compared with the control, the P-values were less than 0.01 as tested by two tailed t-test.
7166 Nucleic Acids Research, 2007, Vol. 35, No. 21not denatured, the naturally occurring, low level of
ssDNA is visualized. Negative control cells were trans-
fected with vectors expressing non-speciﬁc shRNA.
Control cells expressing a normal level of BCCIP
exhibited little positive staining of ssDNA and much of
that staining was apparent in the cytoplasm as reported
by Hammond et al. (28). In contrast, BCCIP knockdown
cells showed dense nuclear punctuate staining
(nuclear foci), indicative of large quantities of ssDNA.
This indicates that BCCIP deﬁciency leads to accumula-
tion of ssDNA, even in the absence of exogenous DNA
damage. It is important to point out that this experiment
was done when the BCCIP expression was only about
50% down-regulated for 2–3 weeks (Figure 4B).
To quantify the level of ssDNA in BCCIP knockdown
cells, the percentage of cells with ﬁve or more ssDNA
nuclear foci were scored. As shown in Figure 4C, there is
a signiﬁcant increase in ssDNA positive cells when BCCIP
is partially knocked-down. Furthermore, the ssDNA and
total DNA ﬂuorescent signals were integrated with ImageJ
software. As shown in Figure 4D, there is a signiﬁcant
increase of ssDNA signals, but no signiﬁcant changes of
total DNA signals, from BCCIP knockdown cells. After
the ssDNA signals were normalized to total DNA, there
remains a signiﬁcant increase of ssDNA signals from the
BCCIP knockdown cells. These quantitative analyses
further support the conclusion that BCCIP knockdown,
at only  50% reduction for 2–3 weeks, signiﬁcantly
increases the level of ssDNA level in the cells.
We reasoned that the high level of ssDNA arising
spontaneously in BCCIP down-regulated cells may be
occurring at stalled or collapsed replication forks that fail
to restart via HR. Because collapsed forks produce DSBs,
we assessed the level of spontaneous DSBs in normal and
BCCIP deﬁcient cells by immuno-staining for gH2AX,
which marks DSB sites (37). We found that control cells
exhibited few gH2AX foci, whereas a large fraction of
BCCIP knockdown cells showed dense gH2AX foci
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Nucleic Acids Research, 2007, Vol. 35, No. 21 7167(Figure 5A). There was a signiﬁcant increase in the
average number of gH2AX foci in BCCIP knockdown
cells (Figure 5B). We also measured the total gH2AX level
in the cell lysate by western blots. As shown in Figure 5C,
there was a signiﬁcant increase of gH2AX when the
BCCIP expression was down-regulated for only  50%.
These results (Figures 4 and 5) indicate that BCCIP has
a critical role in preventing the accumulation of ssDNA
and DSBs resulting from endogenous DNA damage or at
natural replication pause sites. Thus, BCCIP plays critical
roles in maintaining genome stability when cells are
exposed to DNA damaging agents and protects cells
from spontaneous DNA damage arising during normal
cell metabolism.
DISCUSSION
In this study, we made three signiﬁcant ﬁndings that
clarify the function of BCCIP in DSB repair and genome
stabilization. We provide evidence that BCCIP regulates
DSB repair by HR through distinct domains, that BCCIP
functions in HR-mediated gene targeting but not random
integration and that BCCIP has critical roles in suppres-
sing the accumulation of spontaneous ssDNA and DSBs.
Transient expression of BCCIP domains that interact
with either BRCA2 or p21 reduced DSB repair by HR and
gene targeting to similar extents (2- to 3-fold) but these
results provide only qualitative information on the
importance of these interactions because of diﬀerences in
fragment expression, stability and cellular location.
Nonetheless, the results indicate that BCCIP regulates
HR by at least two mechanisms perhaps dependent on its
interactions with BRCA2 and p21. Proteins like RAD51
and RAD54 have direct enzymatic roles in HR, whereas
other proteins play a support role and are often called
‘mediators’. In mammalian cells, BRCA2 is a HR
mediator that facilitates the exchange of RPA with
RAD51 on ssDNA to form RAD51 nucleoprotein
ﬁlaments critical for the homology search and invasion
into homologous donor duplex DNA. BCCIP appears to
mediate HR as well, perhaps by interacting with BRCA2
and promoting BRCA2 function through its interactions
with BRCA2. In this regard, it is interesting that BCCIP
interacts with BRCA2 in the most highly conserved region
of BRCA2 that includes three RPA-like ssDNA binding
domains (11,16). These RPA-like domains are hypothe-
sized to facilitate the exchange of RPA bound to ssDNA
with RAD51 in a ‘hand-oﬀ’ mechanism. It is likely
that expression of BRCA2-interacting fragments of
BCCIP interferes with the normal BRCA2-BCCIP
interaction, thus inhibiting RAD51 loading onto ssDNA
and HR. This model is consistent with the ﬁnding that
RAD51 focus formation is defective in BCCIP-deﬁcient
cells (16).
HR is tightly coordinated with DNA replication,
mitosis and other cell cycle events, but the proteins that
coordinate these processes remain largely unknown.
BRCA2 has been proposed to coordinate HR with
the cell cycle through cyclin-dependent kinase-mediated
phosphorylation of the BRCA2 exon 27 domain
(Ser 3291), which regulates RAD51 binding to this
domain (8). As noted earlier, BCCIP interacts with
BRCA2 not in exon 27 domain but in the conserved
DNA binding domain. However, we cannot rule out
BCCIP inﬂuencing RAD51 binding in the exon 27 domain
because the partial BRCA2 crystal structure did not
include the exon 27 domain (Yang 2002). We previously
reported that BCCIP may regulate p21 function by
multiple mechanisms, including p21 stability and its
expression via p53 (13,31,38). Partial down-regulation
of BCCIP abrogates G1/S checkpoint activation in
response to DNA damage (31). Here, we show that the
expression of a BCCIP p21 interaction domain also
inhibits HR. Because p21 has important roles in cell
cycle regulation, this BCCIP-p21 interaction has strong
potential for coordinating HR with the cell cycle, or
perhaps with cell-cycle checkpoint functions, which
include both cell cycle arrest and induction of DNA
repair.
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in HR probably depend on its interaction with BRCA2
(39,40), whereas its roles in NHEJ remain largely
undeﬁned. Yanez et al. (25) reported that over-expression
of human RAD51 increases gene targeting but does
not aﬀect random integration, suggesting that
RAD51 function is limited to HR. We found that
BCCIP is important for gene targeting but not random
integration. Thus, unlike BRCA1, BCCIP appears to
function only in HR. The dominant negative eﬀects on
HR of BRCA2-interacting fragments of BCCIP suggests
that one key BCCIP function in HR depends on its
interaction with BRCA2 to facilitate RAD51 loading
onto ssDNA (16).
In addition to its role in repair of radiation- and
nuclease-induced DSBs, HR is critical for restarting
stalled or collapsed replication forks. Here, we show
that down-regulation of BCCIP leads to the accumulation
of ssDNA. This ssDNA could arise if a stalled replication
fork is not restarted in timely manner, as continued
replication on the unblocked strand could produce long
stretches of ssDNA on the blocked strand. During normal
replication, short stretches of ssDNA are bound by RPA,
with RAD51 exchange required for strand invasion
and fork restart. In BCCIP deﬁcient cells, this RAD51
exchange is likely to be defective (16), resulting in ssDNA
accumulation. Another mechanism for ssDNA accumula-
tion depends on stalled forks collapsing to a DSB.
In wild-type cells, broken ends are processed to long
ssDNA tails in preparation for RAD51-dependent strand
invasion and fork restart, but in BCCIP-deﬁcient cells,
RAD51 loading is defective, resulting in increased levels
of ssDNA and DSBs. The gH2AX marks DSB sites and
acts as a damage signal that may recruit and enhance
retention of repair factors. Our ﬁnding that gH2AX levels
are greatly enhanced in BCCIP-deﬁcient cells in the
absence of exogenous DNA damaging agents (Figure 5)
is consistent with the idea that BCCIP plays a key role
in HR-dependent restart of stalled or collapsed replication
forks. This idea is further supported by evidence
that BCCIP interacts with BRCA2 constitutively (16),
arguing that these proteins function together to resolve
replication problems that occur normally during S phase.
An interesting observation is that only  50% down-
regulation of BCCIP expression leads to the accumulation
of spontaneous ssDNA and DSB within 2–3 weeks
(Figures 4 and 5). This is consistent with the previously
reported defect in homologous recombination, when
BCCIP expression was constitutively but partially down-
regulated (16). It is in contrast with the recently reported
immediate cytokinesis failure and centrosome ampliﬁca-
tion, when the BCCIP expression is severely down-
regulated (at  90%) (21). Thus, it is possible that diﬀerent
degree of BCCIP down-regulation may have distinct
functional consequences to the cells.
In summary, our data support a model in which BCCIP
regulates HR through multiple mechanisms involving
contacts with BRCA2 and p21 and that these proteins are
part of a network that links HR to cell cycle regulation,
DNA damage checkpoint function, and DNA replication.
The fact that BCCIP deﬁciency results in high levels of
ssDNA and DSBs indicates that BCCIP operates in a
constitutive fashion to maintain genome stability by
promoting HR-dependent replication fork restart and
DSB repair.
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